Investigational drug · Phase 2
TNG462
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for MTAP-deleted Solid Tumors, Locally Advanced Solid Tumor, PDAC.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "TNG462"
First trial start
2023
May 26, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TNG462", any sponsor or status.
Conditions studied
As listed on its trial records.
- MTAP-deleted Solid Tumors
- Locally Advanced Solid Tumor
- PDAC
- PDAC - Pancreatic Ductal Adenocarcinoma
- NSCLC
- RAS Mutation
- MTAP Deletion
- Lung Cancer
- Pancreatic Cancer Metastatic
- Thoracic Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TNG462" as an intervention, largest first.
Tango Therapeutics, Inc.Industry
NCT05732831 · 225 participants (planned) · Start May 26, 2023 · Primary completion Jun 2027
Drug: TNG462; Pembrolizumab · For: Locally Advanced Solid Tumor
Sites: Palo Alto, California; Grand Junction, Colorado; Lake Mary, Florida · 26 sites in all
- TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC PatientsNot yet recruiting
Tango Therapeutics, Inc.Industry
NCT07897734 · 188 participants (planned) · Start Nov 2026 · Primary completion Nov 2031
Drug: vopimetostat; ERAS-0015 · For: PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC and 5 more
Tango Therapeutics, Inc.Industry
NCT06922591 · 183 participants (planned) · Start May 31, 2025 · Primary completion Jun 2027
Drug: TNG462; RMC-9805 and 3 more · For: PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC and 5 more
Sites: Scottsdale, Arizona; Denver, Colorado; Washington D.C., District of Columbia · 18 sites in all
- S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAPActive, not recruiting
Servier Bio-Innovation LLCIndustry
NCT06188702 · 61 participants · Start Apr 29, 2024 · Primary completion May 1, 2027
Drug: S095035; TNG462 · For: MTAP-deleted Solid Tumors
Sites: Lake Mary, Florida; Indianapolis, Indiana; Maumee, Ohio · 20 sites in all
- Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLCNot yet recruiting
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT07938463 · 30 participants (planned) · Start Apr 30, 2027 · Primary completion Nov 30, 2027
Drug: TNG462 vopimetostat; Lorlatinib · For: ALK Positive Non-small Cell Lung Cancer
Sites: Boston, Massachusetts · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models.
Zhang X, Borcherding DC, Zhang M, et al. · Clin Cancer Res 2025
- Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion.
Cottrell KM, Briggs KJ, Tsai A, et al. · J Med Chem 2025
Also in development for MTAP-deleted Solid Tumors
- BAY 3713372Phase 21 trial
Bayer · MTAP-deleted Solid Tumors
- S095035Phase 21 trial
Servier Bio-Innovation LLC · MTAP-deleted Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.